EP Patent

EP4548913A1 — A monolayer tablet of linagliptin and metformin

Assigned to Genepharm SA · Expires 2025-05-07 · 1y expired

What this patent protects

A monolayer tablet comprising metformin granules and linagliptin granules, wherein the linagliptin granules are coated with a basic butylated methacrylate copolymer and the process of its preparation.

USPTO Abstract

A monolayer tablet comprising metformin granules and linagliptin granules, wherein the linagliptin granules are coated with a basic butylated methacrylate copolymer and the process of its preparation.

Drugs covered by this patent

Patent Metadata

Patent number
EP4548913A1
Jurisdiction
EP
Classification
—
Expires
2025-05-07
Drug substance claim
No
Drug product claim
No
Assignee
Genepharm SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.